Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women

Liz Maria de Almeida, Sandra Cortés, Marta Vilensky, Olivia Valenzuela, Laura Cortes-Sanabria, Mirian de Souza, Rafael Alonso Barbeito, Eliana Abdelhay, Nora Artagaveity, Adrian Daneri-Navarro, Andrea S. Llera, Bettina Müller, Osvaldo L. Podhajcer, Carlos Velazquez, Elsa Alcoba, Isabel Alonso, Alicia I. Bravo, Natalia Camejo, Dirce Maria Carraro, Mónica Castro, Sandra Cataldi, Alfonso Cayota, Mauricio Cerda, Alicia Colombo, Susanne Crocamo, Alicia Del Toro-Arreola, Raúl Delgadillo-Cristerna, Lucia Delgado, Marisa Dreyer Breitenbach, Elmer Fernández, Jorge Fernández, Wanda Fernández, Ramon A. Franco-Topete, Fancy Gaete, Jorge Gómez, Leivy P. Gonzalez-Ramirez, Marisol Guerrero, Susan A. Gutierrez-Rubio, Beatriz Jaffín, Alejandra Lopez-Vazquez, Dora Loria, Silvia Miguez, Andres de J. Moran-Mendoza, Gilberto Morgan-Villela, Carina Mussetti, Maria Aparecida Nagai, Antonio Oceguera-Villanueva, Rui M. Reis, Javier Retamales, Robinson Rodriguez, Cristina Rosales, Efrain Salas-Gonzalez, Laura Segovia, Juan M. Sendoya, Aida A. Silva-Garcia, Stella Viña, Livia Zagame, Beth Jones, Moysés Szklo, and United States-Latin American Cancer Research Network (US-LACRN)

1 Instituto Nacional de Cáncer, Rio de Janeiro, Brazil, 2 Pontificia Universidad Católica de Chile, Santiago, Chile, 3 Instituto de Oncología Angel Roffo, Buenos Aires, Argentina, 4 Universidad de Sonora, Hermosillo, Mexico, 5 Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico, 6 Facultad de Medicina, Montevideo, Uruguay, 7 Hospital de Clínicas Manuel Quintela, Universidad de la República, Montevideo, Uruguay, 8 Hospital de Guadalajara, Guadalajara, Mexico, 9 Fundación Instituto Leloir, CONICET, Buenos Aires, Argentina, 10 Instituto Nacional del Cáncer, Santiago, Chile, 11 Hospital Municipal de Oncología María Cuné, Buenos Aires, Argentina, 12 Centro Hospitalario Pereira Rossell, Montevideo, Uruguay, 13 Hospital Regional de Aguadillas Eva Perón, Buenos Aires, Argentina, 14 AC Camargo Cancer Center, São Paulo, Brazil, 15 Instituto Nacional de Cáncer, Montevideo, Uruguay, 16 Institut Pasteur de Montevideo, Montevideo, Uruguay, 17 Universidad de Chile, Santiago, Chile, 18 Universidad de la República, Montevideo, Uruguay, 19 Université Paris-Sud, Orsay, France, 20 Centro de Investigaciones Biológicas y Unidades de Genética de la Universidad de la República, Montevideo, Uruguay, 21 Hospital Provincial de Guadalajara, Guadalajara, Mexico, 22 Hospital Luis Tisne, Santiago, Chile, 23 Texas A&M University, Houston, TX, United States, 24 Hospital San José, Santiago, Chile, 25 Hospital de Gineco-Obstetricia CMNO-IMSS, Guadalajara, Mexico, 26 Registro Nacional de Cáncer, Montevideo, Uruguay, 27 Instituto de Cáncer de Sao Paulo, Sao Paulo, Brazil, 28 Instituto Jallionense de Cancerología, Guadalajara, Mexico, 29 Hospital de Cáncer de Barretos, Barretos, Brazil, 30 Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile, 31 Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay, 32 Hospital Barros Luco Trudeau, Santiago, Chile, 33 Yale School of Public Health, Yale University, New Haven, CT, United States, 34 Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States

Molecular profile of breast cancer in Latin-American women was studied in five countries: Argentina, Brazil, Chile, Mexico, and Uruguay. Data about socioeconomic characteristics, risk factors, prognostic factors, and molecular subtypes were described, and the 60-month overall cumulative survival probabilities (OS) were estimated. From 2011 to 2013,
1,300 eligible Latin-American women 18 years or older, with a diagnosis of breast cancer in clinical stage II or III, and performance status $\leq 1$ were invited to participate in a prospective cohort study. Face-to-face interviews were conducted, and clinical and outcome data, including death, were extracted from medical records. Unadjusted associations were evaluated by Chi-squared and Fisher’s exact tests and the OS by Kaplan–Meier method. Log-rank test was used to determine differences between cumulative probability curves. Multivariable adjustment was carried out by entering potential confounders in the Cox regression model. The OS at 60 months was 83.9%. Multivariable-adjusted death hazard differences were found for women living in Argentina (2.27), Chile (1.95), and Uruguay (2.42) compared with Mexican women, for older ($\geq 60$ years) (1.84) compared with younger ($< 40$ years) women, for basal-like subtype (5.8), luminal B (2.43), and HER2-enriched (2.52) compared with luminal A subtype, and for tumor clinical stages IIB (1.91), IIA (3.54), and IIB (3.94) compared with stage IIA women. OS was associated with country of residence, PAM50 intrinsic subtype, age, and tumor stage at diagnosis. While the latter is known to be influenced by access to care, including cancer screening, timely diagnosis and treatment, including access to more effective treatment protocols, it may also influence epigenetic changes that, potentially, impact molecular subtypes. Data derived from heretofore understudied populations with unique geographic ancestry and sociocultural experiences are critical to furthering our understanding of this complexity.

**Keywords**: global excellence, oncology, Latin America, breast cancer, molecular subtypes, risk factors, prognosis

**INTRODUCTION**

Breast cancer is the leading cause of death from cancer in women worldwide and in Latin America (1). Breast tumors can be stratified by histological and immunopathological as well as by molecular subtypes (2). Socioeconomic and cultural-mediated factors contribute to breast cancer heterogeneity survival (3–6). Advanced stage at diagnosis, high grade, negative hormone receptors, and HER-2 amplification have been found to be associated with higher breast cancer mortality (7).

Studies of Latin American women have shown differences in the distribution of molecular subtypes of breast cancer by geographic regions (8) which reflect differences in genetic background of the population (9). Data from heretofore understudied populations with unique geographic ancestry and sociocultural experiences are critical to furthering our understanding of this population heterogeneity (10).

Latin American women have a lower incidence but higher mortality from breast cancer than those observed in women from developed countries, except in Argentina and Uruguay, where the incidences are higher than in Latin America countries (Supplementary Figure S1) (11, 12). Estimates of breast cancer survival in 2010–2014 were 84.4%, 75.5%, and 75.2% for Argentina, Chile, and Brazil (13).

To better understand the characteristics and survival of Latin American women with breast cancer, epidemiologists from Argentina, Brazil, Chile, Mexico, Uruguay, and the USA conducted the Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment (MPBC) study, proposed by the US-Latin America Cancer Research Network (US-LACRN) (14). The goal of this study was to describe the characteristics of the Latin American women with breast cancer by country and to identify predictors for 60-month cumulative probability of overall survival. To our knowledge, this is the first comprehensive, multisite study focusing on Latin American breast cancer patients including molecular, clinical, and epidemiological profiles to overall (all-cause) survival.

**MATERIAL AND METHODS**

**Study Design**

Between 2011 and 2013, a prospective cohort study was conducted in Argentina, Brazil, Chile, Mexico, and Uruguay, where eligible women with recently diagnosed breast cancer were recruited from reference cancer treatment centers. Using standardized questionnaire, trained interviewers collected epidemiological data. In addition to molecular profiling of tumor tissue described in an earlier publication (14), clinical data were collected from medical records. Women were followed up through death from any cause for 5 years (Supplementary Figure S2).

**Settings**

Three hospitals in Argentina (two in the Autonomous City of Buenos Aires and one in Buenos Aires Province), four in...
Brazilians cities (one in Rio de Janeiro, two in São Paulo, and one in Barretos), eleven in Mexico cities (six in Hermosillo, one in Obrógén, and four in Guadalajara), four in Chile in the Metropolitan Area of Santiago, and four in Montevideo (Uruguay) were included.

Inclusion and Exclusion Criteria
Eligible Latin American women who were ≥18 years old, reside in the recruiting locations, looking for treatment in the selected hospitals, with a new confirmed histopathological diagnosis of breast cancer, clinical stage II or III, and performance status (PS) ≤1 were invited to participate in the study and, after signing the consent form, were included. Exclusion criteria were prior history of nonbreast malignancy in the previous 5 years, in situ, bilateral invasive or inflammatory breast cancer, and clinical or radiological evidence of distant metastases. Pregnant or lactating women were also ineligible.

Data Collection
The recruitment period in the selected hospitals began in November 2011 and finished in December 2013, including 1,300 women. After signing the consent form, the women were interviewed by nurses in private settings, using an instrument that included questions of socioeconomic and demographic characteristics and lifestyle factors (age, education, alcohol and tobacco use, physical activity, and Body Mass Index), as well as access to healthcare, ancestry, familial cancer, hormonal and reproductive history, medical history, anthropometric data, alcohol intake, tobacco use, and physical activity (Supplementary Material 3). The questionnaire and its instruction manual were translated to English, Spanish, and Portuguese. All versions were cross-compared. Data were stored in Open Clinica® (openclinica.com) and were managed by WESTAT under NCI contract. Clinical-pathological and treatment information registered in CRFs included age, histological type, histological grade, clinical stage, lymph node status, tumor size at diagnosis, estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2) and Ki67 expression, neoadjuvant therapy, and adjuvant therapy. Researchers trained by oncologists abstracted clinical and outcome data, including information on vital status and date of death, during the follow-up. Data managers in each site followed the standardized protocol reviewing and coding free text and notes before data entry and conducting quality checks following data entry. After clinical evaluation, patients were treated according to standard of care of each institution in each country.

Biological Tissue Collection
All sample collection procedures were carried out according to the LACRN consensus standard operating procedures for frozen and formalin-fixed, paraffin-embedded (FFPE) specimens based on the TCGA best practice recommendations (https://brd.nci.nih.gov/brd/sop-compendium/show/701). Tissue samples were obtained from core needle biopsies or from surgical resections.

PAM50 Subtype Assignation
PAM50 subtype assignation was performed with gene expression data obtained from two-color Agilent 4x44k v2 microarrays (15). A training set of balanced ER+ and ER− cases sampled from all countries was used for centering the gene expression data of the whole cohort, and the PAM50 algorithm was run as described elsewhere (https://genome.unc.edu/pubsup/breastGEO/PAM50.zip). Each site performed gene expression analysis independently with their own equipment, after a thorough harmonization of all the molecular aspects related to sample obtention, storage, RNA extraction, and microarray analysis.

Data Analysis
From the 1,300 patients of the cohort, 1,140 answered the epidemiological questionnaire. From these, 177 patients were excluded from the analysis due to lack of gene expression and PAM50 data, and 64, due to lack of clinical staging. The analytic sample of this epidemiological study consisted of 863 breast cancer patients.

The sociodemographic variables were described as follows: (a) Age: less than 40 years, 40–49, 50–59, and 60 years and over; (b) education: 0–8 completed years, 9–24, and unknown; and (c) Body Mass Index: <25.0, 0–29.99 kg/m², ≥30.0 kg/m², and unknown. Lifestyle variables: alcohol use: none, any, and unknown; tobacco use: never smoke, smoker, ex-smoker, and unknown; and physical activity: no, yes, and unknown. Reproductive, hormonal, and breast cancer history variables: age range at menarche: ≤12 years and ≥13 years and over; use of oral contraceptives: ever use vs. never use; at least one full-term pregnancy, breastfeeding, hormone replacement therapy, self-reported previous benign breast diseases, and first-degree family history of breast cancer: yes vs. no; menopause status: premenopausal vs. postmenopausal; and type of menopause: natural causes vs. surgery or other reasons.

Molecular and clinical characteristics of the tumor were classified according to the PAM50 in: luminal A, luminal B, HER2-enriched, basal-like, and normal-like subtypes. Gene expression distribution of PAM50 genes in all samples were previously tested by principal component analysis to confirm that there were no associations with potential sources of bias such as country, arm (neoadjuvant or adjuvant therapy), processing date, or sample quality. Clinical stage at diagnosis was stratified as IIA, IIB, IIIA, and IIIC.

Unadjusted associations between country of residence and selected characteristics were evaluated by Chi-squared and Fisher’s exact tests ($p < 0.05$). Overall 60-month cumulative survival probability (OS) was estimated by the Kaplan–Meier method. Follow-up started with the informed consent form signature. Women were followed up through death, loss to follow-up, or end of the study. Cumulative probabilities based on less than 10 patients, e.g., HER2-enriched and basal-like subtypes in Uruguay were not examined. The log-rank test was
used to determine the differences between the estimated cumulative probability curves. Variables with p-values <0.20 were entered in the multivariable-adjusted Cox proportional hazards model (adjusted by country of residence, age, education, PAM50 intrinsic subtype, and tumor clinical stage). The proportional-hazards assumption over time was evaluated by a test based on Schoenfeld residuals. Stata 15 was used to perform all analyses (16).

Ethics Issues
Local ethics committee of the institutions of each country (18 centers) and the National Cancer Institute ethics committee approved this study (Supplementary Material 4). All participants who agreed to participate signed informed consent forms.

RESULTS

General and Between-Country Differences in Breast Cancer Risk Factors
The majority (65%) of Latin American women were aged 50 years and over (median = 54 years old, 1st quartile = 45, and 3rd quartile = 62) and never used alcohol (63%) or tobacco (57%). Fifty-two percent were not physically active and 66% were overweight. Differences among the country’s distributions were statistically significant (p-value <0.05) for age group, education level, alcohol and tobacco use, physical activity but not for body mass index (Table 1). Uruguay’s women were older than those from other countries. Chile’s women had a higher proportion of completed years of schooling compared with those from other countries. More than half of the women had ever used tobacco in Uruguay and Chile. In Uruguay and Brazil, women were found to drink alcohol beverages more often than those in other countries. Chile showed the highest proportion of smokers and physically inactive women (Table 1).

Among reproductive factors (Table 2), cross-country differences were statistically significant (p < 0.05) for oral contraceptive use, breastfeeding history, type of menopause, hormone replacement therapy (HRT), self-reported benign breast diseases, and first-degree breast cancer family history. Most women had menarche when older than 12 years and were postmenopausal when younger than 50 years, with 3/4 experiencing natural menopause. Oral contraceptives had been used by 60% of the women. At least 90.2% of the women had one or more full-term pregnancy and 80% had breastfed their children. The vast majority of women had not used hormone replacement therapy.

### TABLE 1 | Distribution of Latin American women with breast cancer by country of residence, according to sociodemographic and lifestyle factors.

| Sociodemographic and lifestyle factors | Argentina | Brazil | Chile | Mexico | Uruguay | Total | p-value |
|----------------------------------------|-----------|--------|-------|--------|---------|-------|--------|
|                                        | n | %   | n | %   | n | %   | n | %   | n | %   | n | %   | n.a. |
| Total                                  | 209 | 24.2 | 203 | 23.5 | 149 | 17.3 | 234 | 27.1 | 68 | 7.9 | 863 | 100.0 |
| Age group                              |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| Less than 40 years                     | 19 | 9.1  | 24 | 11.8 | 13 | 8.7  | 30 | 12.8 | 6 | 8.8  | 92 | 10.7 | 0.006 |
| 40 to 49 years                         | 46 | 22.0 | 46 | 22.7 | 30 | 20.1 | 73 | 31.2 | 13 | 19.1 | 208 | 24.1 |
| 50 to 59 years                         | 71 | 34.0 | 76 | 37.4 | 48 | 32.2 | 73 | 31.2 | 15 | 22.1 | 283 | 32.8 |
| 60 years and over                      | 73 | 34.9 | 57 | 28.1 | 58 | 38.9 | 58 | 24.8 | 34 | 50.0 | 280 | 32.4 |
| Education                              |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| 0 to 8 years                           | 105 | 50.2 | 114 | 56.2 | 54 | 36.2 | 122 | 52.1 | 41 | 60.3 | 436 | 50.5 | 0.003* |
| 9 to 24 years                          | 104 | 49.8 | 88 | 43.3 | 91 | 61.1 | 107 | 47.9 | 27 | 39.7 | 417 | 49.5 |
| Unknown                                | 0 | 0.0  | 1 | 0.5  | 4 | 2.7  | 5 | 2.1  | 0 | 0.0  | 10 | 1.2  |
| Alcohol use                            |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| None                                   | 126 | 60.3 | 98 | 48.3 | 99 | 66.4 | 189 | 80.8 | 30 | 44.1 | 542 | 62.8 | <0.001* |
| Any                                    | 77 | 36.8 | 105 | 51.7 | 45 | 30.2 | 43 | 18.4 | 36 | 52.9 | 306 | 35.5 |
| Unknown                                | 6 | 2.9  | 0 | 0.0  | 5 | 3.4  | 2 | 0.9  | 2 | 2.9  | 15 | 1.7  |
| Tobacco use                            |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| Never smoke                            | 117 | 56.0 | 126 | 62.1 | 61 | 40.9 | 162 | 69.2 | 29 | 42.6 | 495 | 57.4 | <0.001* |
| Smoker                                 | 39 | 18.7 | 23 | 11.3 | 37 | 24.8 | 14 | 6.0  | 13 | 19.1 | 126 | 14.6 |
| Ex-smoker                              | 50 | 23.9 | 54 | 26.6 | 50 | 33.6 | 57 | 24.4 | 24 | 35.3 | 235 | 27.2 |
| Unknown                                | 3 | 1.4  | 0 | 0.0  | 1 | 0.7  | 1 | 0.4  | 2 | 2.9  | 9 | 0.8  |
| Physical activity                      |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| No                                     | 86 | 41.1 | 101 | 49.8 | 85 | 57.0 | 96 | 41.0 | 32 | 47.1 | 400 | 46.3 | 0.014* |
| Yes                                    | 117 | 56.0 | 100 | 49.2 | 63 | 43.2 | 136 | 58.1 | 30 | 44.1 | 446 | 51.7 |
| Unknown                                | 6 | 2.9  | 2 | 1.0  | 1 | 0.7  | 2 | 0.9  | 6 | 8.8  | 17 | 2.0  |
| Body Mass Index (BMI)                  |    |      |    |      |    |      |    |      |    |      |    |      | n.a. |
| <25.0 kg/m\(^2\)                        | 62 | 29.7 | 55 | 27.1 | 35 | 23.5 | 57 | 24.4 | 17 | 25.0 | 226 | 26.2 | 0.268* |
| 25.0–29.99 kg/m\(^2\)                   | 71 | 34.0 | 72 | 35.5 | 57 | 38.3 | 88 | 37.6 | 15 | 22.1 | 303 | 35.1 |
| ≥30.0 kg/m\(^2\)                        | 59 | 28.2 | 59 | 29.1 | 50 | 33.6 | 71 | 30.3 | 30 | 44.1 | 269 | 31.2 |
| Unknown                                | 17 | 8.1  | 17 | 8.4  | 7 | 4.7  | 18 | 7.7  | 6 | 8.8  | 65 | 7.5  |

*The p-value of the Chi-square test does not include the unknown category. n.a., Not applicable.
replacement therapy (86.7%). More than half reported benign breast diseases (57.9%) and only 7.3% had a first-degree family history of breast cancer.

The most common tumors were luminal A (42.9%) and luminal B (21.4%) followed by basal-like (16.2%), HER2-enriched subtype (12.7%), and normal-like subtype (6.7%). Percentages of luminal A subtype varied from 36.8% in Mexico to 50.0% in Argentina and 50.2% in Uruguay. Uruguay also showed the highest proportion of luminal B (29.4%). HER2-enriched subtype was high in Mexico (17.1%) and low in Uruguay (8.8%). The highest variability between countries was found for basal-like breast cancer subtype: from 4.4% in Uruguay to 21.4% in Mexico. Fifty-eight breast tumors were classified as normal-like subtype according to PAM50 and the highest proportion was found in Argentina (8.6%). Seventy percent of Latin American women were diagnosed at stage II (38% at IIA, 32% at IIB) and 30% at stage III (20% at IIIA, 10% at IIIB). We observed some differences by country: 61% of Brazil’s and 84% of Uruguay’s women were diagnosed at stage II. Brazil had the highest percentage of women in stage IIIB: 21% (Table 3).

**Overall Cumulative Survival Probabilities for Latin American Women**

The unadjusted OS at 60 months for all Latin American women was 83.9% (95% CI, 81.2–86.2). OS cumulative probabilities were similar among countries, ranging from 81% in Argentina to 88% in Mexico (Table 4).

Statistical differences (log-rank p < 0.05) were observed only for PAM-50 intrinsic subtypes and tumor stage (Table 5). For PAM50 intrinsic subtypes, the OS were estimated as 92% for luminal A, 80% for luminal B, 81% for HER2-enriched, 66% for basal-like, and 89% for normal-like. For tumor staging, the
OS were 92% for IIA, 84% for IIB, 72% for IIIA, and 74% for IIIB.

The OS by country of residence and PAM50 intrinsic subtypes indicated statistically significant differences ($p = 0.010$) only for HER2-enriched subtype (Figure 1). Mexico and Chile had the highest and lowest OS, respectively, for this subtype.

The multivariable-adjusted all-cause hazard ratios (HRs) for country of residence, age group, PAM50 intrinsic subtype, and tumor staging are shown on Table 6. The death hazards of women living in Argentina and Uruguay were more than twice as high as for Mexican women (referent). A similar difference in death hazards was seen between older ($\geq 60$ years) and younger ($\leq 40$ years) women. The HRs for luminal B and HER2-enriched

### Table 3
| Molecular characteristic of the tumor according to PAM50 intrinsic subtype and tumor clinical stage at diagnosis of Latin American women with breast cancer by country of residence. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| A                              | Argentina       | Brazil          | Chile           | Mexico          | Uruguay         | Total           |
| Luminal A                       | 105             | 82              | 63              | 86              | 34              | 370             |
| Luminal B                       | 30              | 14.4            | 26.1            | 29.6            | 18.4            | 185             |
| HER2-enriched                   | 24              | 11.5            | 24.1            | 16.0            | 40              | 110             |
| Basal-like                      | 32              | 15.3            | 33.1            | 16.3            | 22              | 40              |
| Normal-like                     | 18              | 8.6             | 11.5            | 9.0             | 6.0             | 58              |
| Clinical stage at diagnosis     |                 |                 |                 |                 |                 |                 |
| IIA                             | 92              | 44.0            | 90              | 44.3            | 46              | 28.6            |
| IIB                             | 60              | 28.7            | 35              | 17.2            | 58              | 38.9            |
| IIIA                            | 43              | 20.6            | 35              | 17.2            | 35              | 23.5            |
| IIIB                            | 14              | 6.7             | 43              | 21.2            | 10              | 6.7             |

### Table 4
| Overall cumulative survival probability at 60 months of Latin American women with breast cancer according to sociodemographic characteristics and lifestyle factors. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Sociodemographic and lifestyle factors | Cumulative survival probability at 60 months (PS60) | Log-rank $p$-value |
| PS60                            | 95% CI          |                  |
| Global                          | 83.9            | (81.2–86.2)      | n.a.            |
| Country of residence            |                 |                  |
| Argentina                       | 80.9            | (74.4–85.9)      | 0.402           |
| Brazil                          | 84.0            | (78.1–88.4)      |                 |
| Chile                           | 81.9            | (74.7–87.2)      |                 |
| Mexico                          | 87.8            | (82.6–91.5)      |                 |
| Uruguay                         | 82.9            | (71.2–90.2)      |                 |
| Age group                       |                 |                  |
| Less than 40 years              | 83.7            | (74.1–90.0)      | 0.799           |
| 40 to 49 years                  | 85.2            | (79.4–89.5)      |                 |
| 50 to 59 years                  | 84.7            | (79.8–88.5)      |                 |
| 60 years and over               | 82.2            | (77.0–86.3)      |                 |
| Education                       |                 |                  |
| 0 to 8 years                    | 81.6            | (77.5–85.0)      | 0.074           |
| 9 years or more                 | 86.5            | (82.7–89.5)      |                 |
| Alcohol use                     |                 |                  |
| None                            | 85.4            | (82.0–88.2)      | 0.248           |
| Any                             | 82.1            | (77.1–86.1)      |                 |
| Tobacco use                     |                 |                  |
| Never smoke                     | 85.2            | (81.6–88.1)      | 0.372           |
| Smoker                          | 83.6            | (75.5–89.2)      |                 |
| Ex-smoker                       | 80.9            | (75.1–85.5)      |                 |
| Physical activity               |                 |                  |
| No                              | 83.8            | (79.7–87.2)      | 0.864           |
| Yes                             | 84.1            | (80.2–87.2)      |                 |
| Body mass index                 |                 |                  |
| $<25.0$ kg/m$^2$                | 84.7            | (79.1–89.0)      | 0.357           |
| $25.0–29.9$ kg/m$^2$            | 82.6            | (77.7–86.5)      |                 |
| $\geq 30.0$ kg/m$^2$            | 86.8            | (82.0–90.4)      |                 |

n.a., Not applicable.
subtypes were also twice as high as that for luminal A subtype. Death HR for basal-like subtype was 5.8 when compared with luminal A. As expected, death HRs for women diagnosed with clinical stages IIB, IIIA, and IIIB were higher than those diagnosed with stage IIA.

**General and Between-PAM50 Differences in Breast Cancer Risk Factors**

Sociodemographic characteristics, lifestyle, reproductive and hormonal characteristics, family history of breast cancer, as well as tumor characteristics and treatment according to PAM50 intrinsic subtypes are shown in Tables 7 and 8. Luminal A and luminal B subtypes were more common in women ≥60 years old. HER2-enriched, basal-like, and normal-like were more common in younger women (50–59 years). The highest proportion of ever smokers was observed in luminal A and B subtypes. Differences in PAM50 subtypes by education level, alcohol use, physical activity, and BMI were not statistically significant (Table 7).

Women with stage IIA of breast cancer at diagnosis were more frequent in the luminal A (50.0%) and luminal B (36%) subtypes, while women with basal-like subtype were more frequently diagnosed at stage IIIA (36%). Differences in age range of menarche, use of oral contraceptives, at least one full pregnancy, breastfeeding, menopausal status and age, hormone replacement therapy, previous benign breast diseases, and first-degree family history of breast cancer were not statistically significant between PAM50 subtypes (Table 8).

**DISCUSSION**

This paper reports the first epidemiological and molecular analysis of a study carried out by the LACRN in collaboration with the National Cancer Institute/USA. The general objective of this network is to strengthen collaborative research efforts among the participating countries, advance translational cancer research, and serve as a basis for planning new actions to reduce the global cancer burden, focusing on breast cancer as a priority (14).
With regard to the characteristics of breast cancer included in our study, distribution by age in Latin American women is in line with what has been observed in previous studies, in which the majority of cases have been aged 50 years and older. Age is one of the most important risk factors for breast cancer. It is projected that the number of women aged 60 years and older will double by 2030, with age-unadjusted breast cancer incidence probably following this tendency (12). Uruguay and Argentina had the highest breast cancer rates in Latin American women in 2013 (12). As these rates were age-adjusted, other-than-age demographic, behavioral and reproductive factors may be responsible for the high rates in these countries. In developed countries, the breast cancer incidence rates are high while breast cancer mortality rates are much lower (1).

Almost one-half of women in our study had menarche at age ≤12 years and one in five experienced menopause onset at ages ≥50 years. Last century’s changes in sexual maturation and reproductive patterns have led to an increased exposure to estrogen and progesterone levels, contributing to increased risk of breast cancer (17). Indeed, breast cancer risk increases by 5% for each younger year at menarche and ≈3% for each older year in menopause onset (18). Younger age at menopause has directly been found to be associated with luminal-like tumors but not with HER2-enriched or basal-like subtypes (19).

The majority of Latin American women in our study had at least one full-term pregnancy and breastfed their children, both of which are protective against breast cancer (20).

With regard to the main objective of our study, compared with the death hazard ratio (HR) for luminal A, the death hazards for luminal B and HER-2 enriched subtypes were more than twice as high. The hazard for the basal-like subtype was about 6 times higher than that for luminal A confirming the latter as the least aggressive subtype. Worst cumulative survival probabilities were found for HER2-enriched and basal-like subtypes in a previous study (21).

The overall cumulative survival probability curves by molecular subtypes of breast cancer by country in our study reflected a combination of factors. In addition to molecular subtype, OS also reflected tumor staging and age at diagnosis and clinical and socioeconomic conditions. While socioeconomic status can influence access to care (including access to early diagnosis and to treatment with specific drugs), it may also influence epigenetic changes that influence molecular subtypes (22–25).

FIGURE 1 | Overall cumulative survival probabilities for Latin American women with breast cancer by country of residence and PAM50 intrinsic subtype.
TABLE 6 | Unadjusted and adjusted death hazard ratios of Latin American women with breast cancer by country of residence, age, education, PAM50 intrinsic subtypes, and tumor clinical stage at diagnosis.

| Country of residence | Unadjusted hazard ratio | Adjusted hazard ratio |
|----------------------|-------------------------|-----------------------|
|                      | HR | p-value | 95% CI | HR | p-value | 95% CI |
| Mexico               | 1.00 |          |         | 1.00 |          |         |
| Argentina            | 1.69 | 0.047 | (1.01–2.84) | 2.27 | 0.003 | (1.33–3.86) |
| Brazil               | 1.46 | 0.159 | (0.86–2.48) | 1.58 | 0.107 | (0.91–2.74) |
| Chile                | 1.73 | 0.051 | (1.00–2.99) | 1.95 | 0.021 | (1.11–3.44) |
| Uruguay              | 1.52 | 0.251 | (0.74–3.10) | 2.42 | 0.019 | (1.16–5.04) |
| Age group            |     |          |         |     |          |         |
| Up to 40 years       | 1.00 |          |         | 1.00 |          |         |
| 40 to 49 years       | 0.88 | 0.698 | (0.46–1.67) | 1.07 | 0.846 | (0.56–2.04) |
| 50 to 59 years       | 0.98 | 0.948 | (0.53–1.60) | 1.16 | 0.634 | (0.63–2.15) |
| 60 years and over    | 1.10 | 0.746 | (0.61–2.01) | 1.84 | 0.055 | (0.99–3.42) |
| Education (years)    | 0.97 | 0.177 | (0.94–1.01) | 0.97 | 0.210 | (0.93–1.02) |
| PAM50 intrinsic subtype |     |          |         |     |          |         |
| Luminal A            | 1.00 |          |         | 1.00 |          |         |
| Luminal B            | 2.78 | <0.001 | (1.67–4.64) | 2.43 | 0.001 | (1.44–4.10) |
| HER2-enriched        | 2.72 | 0.001 | (1.51–4.92) | 2.52 | 0.003 | (1.37–4.63) |
| Basal-like           | 5.76 | <0.001 | (3.54–9.35) | 5.79 | <0.001 | (3.48–9.64) |
| Normal-like          | 1.52 | 0.359 | (0.62–3.68) | 1.32 | 0.543 | (0.54–3.26) |
| Tumor clinical stage at diagnosis |     |          |         |     |          |         |
| IIA                  | 1.00 |          |         | 1.00 |          |         |
| IIB                  | 2.11 | 0.004 | (1.27–3.51) | 1.91 | 0.015 | (1.32–3.24) |
| IIIA                 | 4.19 | <0.001 | (2.55–6.86) | 3.54 | <0.001 | (2.10–5.98) |
| IIIB                 | 3.92 | <0.001 | (2.17–7.10) | 3.94 | <0.001 | (2.14–7.24) |

Obs: the death hazard ratio for each variable is simultaneously and reciprocally adjusted for all other variables.

Women were treated according to the institutions’ standard protocols, in which the access to some expensive drugs depends on the healthcare organization in each country and on individual health insurance. These are likely reasons why some breast cancer patients in Chile and Argentina did not receive specific drugs that are known to improve the prognosis (26). Access to diagnosis and treatment makes it possible for women with breast cancer to be diagnosed at an earlier stage, which would improve their survival. Identification of molecular profiles at diagnosis is particularly important because they result in the implementation of more efficacious treatment protocols. This likely impacted the OS in these countries, especially in women with the HER2-enriched subtype of breast cancer.

Life expectancy at birth is the integrated survivorship of the population across all ages, and it is used as a proxy of population health (27). Life expectancy has significant effect on per capita income as well as its growth. Education is also positively associated with the per capita income. High prevalence of the disease burden in working age group implies a significant loss of human capital which impairs its contribution to economic production (28). Other studies demonstrated that GPD per capita and education level explain 72.6% to 82.6% differences in life expectancy at birth (29). In 2010, Chile and Uruguay had the highest life expectancy of women at birth, and, in 2013, Chile and Argentina had the highest GPD per capita and Human Development Index (Supplementary Figure S1). Yet, in our study, women with breast cancer in Mexico and Brazil showed higher overall cumulative survival than Argentina, Chile, and Uruguay. One possible factor, not explored here, is differences in genetic susceptibility in these countries. Fejerman et al. (30) evaluated the association between genetic ancestry and survival after breast cancer diagnosis among US Latin American women and concluded that genetic factors and/or unmeasured differences in treatment or access to care should be explored to better understand disparities in breast cancer outcome (30). To evaluate these factors, we are developing new molecular studies related to ancestry in these women. Other important prognostic factors that should be explored in future studies are the organization of the health system and women’s behavior related to preventive practices as well as their access to healthcare.

A major strength of the study was its multicenter feature and careful development of the questionnaire and the implementation of standardized protocols in five different countries. Although this study was conducted over a large and diverse geographic area, results are likely generalizable to women who receive their breast cancer care in similar healthcare settings. All protocols for the tumor molecular characterization were standardized in order to establish the PAM50 or set of 50 “intrinsic” genes that allowed the classification of breast cancer subtypes to be hypothesized as prognostic factors.

Among the study limitations, there was the loss of epidemiological, clinical, and molecular information. Identifying a series of 863 breast cancer cases across five major geographic areas may influence precision of our findings, especially with regard to between-country comparisons. Another potential limitation includes the differences in health systems, social determinants of health, and inequity in access to healthcare or supply of appropriated therapies. Notwithstanding this limitation,
we believe that the evidence generated in this study is of value for all countries and may help in improving identification and treatment of breast cancer.

In conclusion, the overall cumulative survival in our study was associated with molecular subtype of the tumor, age, and tumor stage at diagnosis. The latter can reflect contextual variables that, in turn, likely influence access to early diagnosis and treatment of the breast cancer. While the latter is known to be influenced by access to care, including cancer screening, timely diagnosis, and treatment, as well as access to more effective treatment protocols (22–24), it may also influence epigenetic changes that, potentially, can impact molecular subtypes.

TABLE 7 | Distribution of Latin American women with breast cancer by PAM50 subtypes according to sociodemographic and lifestyle factors.

| Sociodemographic and lifestyle                  | Luminal A | Luminal B | HER2-enriched | Basal-like | Normal-like | Total |
|------------------------------------------------|-----------|-----------|---------------|------------|-------------|-------|
| n %                                            | n %       | n %       | n %           | n %        | n %         |       |
| Total                                          | 370 42.9  | 185 21.4  | 110 12.7      | 140 16.2   | 58 6.7      | 863   |
| Country of residence                           |           |           |               |            |             |       |
| Argentina                                      | 105 28.4  | 30 16.2   | 24 21.8       | 32 22.9    | 18 31.0     | 209   |
| Brazil                                         | 82 22.2   | 53 28.6   | 24 21.8       | 33 23.6    | 11 19.0     | 203   |
| Chile                                          | 63 17.0   | 39 21.1   | 16 14.5       | 22 15.7    | 9 15.5      | 149   |
| Mexico                                         | 86 23.2   | 43 23.2   | 40 36.4       | 50 35.7    | 15 25.9     | 234   |
| Uruguay                                        | 34 9.2    | 20 10.8   | 6 5.5         | 3 2.1      | 5 8.6       | 86    |
| Age group                                      |           |           |               |            |             |       |
| Less than 40 years                             | 31 8.4    | 8 2.2     | 9 8.2         | 21 15.0    | 6 10.3      | 92    |
| 40 to 49 years                                 | 85 23.0   | 36 19.5   | 25 22.7       | 45 32.1    | 17 29.3     | 208   |
| 50 to 59 years                                 | 104 28.1  | 54 29.2   | 47 42.7       | 52 37.1    | 26 44.8     | 283   |
| 60 years and over                              | 150 40.5  | 70 37.8   | 29 26.4       | 22 15.7    | 9 15.5      | 280   |
| Education                                      |           |           |               |            |             |       |
| 0 to 8 years                                   | 189 51.1  | 86 46.5   | 60 54.5       | 70 50.0    | 31 53.4     | 436   |
| 9 to 24 years                                  | 177 47.8  | 94 50.8   | 50 45.5       | 69 49.3    | 27 46.6     | 417   |
| Unknown                                        | 4 1.1     | 5 2.7     | 0 0.0         | 1 0.7      | 0 0.0       | 10    |
| Alcohol use                                    |           |           |               |            |             |       |
| None                                           | 230 62.2  | 111 60.0  | 73 66.4       | 90 64.3    | 38 65.5     | 542   |
| Any                                            | 134 36.2  | 70 37.8   | 33 30.0       | 49 35.0    | 20 34.5     | 306   |
| Unknown                                        | 6 1.6     | 4 2.2     | 4 3.8         | 1 0.7      | 0 0.0       | 15    |
| Tobacco use                                    |           |           |               |            |             |       |
| Never smoke                                    | 196 53.0  | 97 52.4   | 73 66.4       | 87 62.1    | 42 72.4     | 495   |
| Smoker                                         | 64 17.3   | 26 14.1   | 16 14.5       | 14 10.0    | 6 10.3      | 126   |
| Ex-smoker                                      | 108 29.2  | 59 31.9   | 20 18.2       | 38 27.1    | 10 17.2     | 235   |
| Unknown                                        | 2 0.5     | 3 1.8     | 1 0.9         | 1 0.7      | 0 0.0       | 7     |
| Physical activity                              |           |           |               |            |             |       |
| No                                             | 173 46.8  | 92 49.7   | 48 43.6       | 58 41.4    | 29 50.0     | 400   |
| Yes                                            | 191 51.6  | 86 46.5   | 58 52.7       | 82 58.6    | 29 50.0     | 446   |
| Unknown                                        | 6 1.6     | 7 3.8     | 4 3.6         | 0 0.0      | 0 0.0       | 17    |
| Body mass index                                |           |           |               |            |             |       |
| <25.0 kg/m²                                     | 104 28.1  | 44 23.8   | 31 28.2       | 33 23.6    | 14 24.1     | 226   |
| 25.0–29.9 kg/m²                                 | 128 34.6  | 64 34.6   | 41 37.3       | 50 35.7    | 21 36.2     | 304   |
| ≥30.0 kg/m²                                     | 116 31.4  | 67 38.2   | 24 21.8       | 45 32.1    | 17 29.3     | 269   |
| Unknown                                        | 22 5.9    | 10 5.4    | 14 12.7       | 12 8.6     | 6 10.3      | 64    |

*The p-value of the Chi-square test does not include the category unknown.

n.a., Not applicable.

UNITED STATES-LATIN AMERICAN CANCER RESEARCH NETWORK (US-LACRN)

Juan Abarca (Hospital Barros Luco Trudeau, Santiago, Chile), Pamela Acevedo (Hospital San José, Santiago, Chile), Graciela Acosta (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Ana Acosta (Universidad de Sonora, Hermosillo, Mexico), Gabriela Acosta Haab (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Keyla Teresa Acosta-Torres (Hospital General Zona 2, IMSS, Hermosillo, México), Marta Aghazarian (Instituto Nacional de Cáncer, Montevideo, Uruguay), Carola Agüayo (Instituto de Salud Pública, Santiago, Chile), Gustavo Alarcon-Lopez (Hospital Integral de la Mujer en Estado de Sonora, Hermosillo, México), Viviane Andrade (Hospital de Cáncer de Barretos, Barretos, Brazil), Wenceslao Angeles-Bueno (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), Roberto Araí (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Priscila Elvira Arambula-Barreras (Universidad de Sonora, Hermosillo, Mexico), Maria Isabel Aramburo-Rubio (Hospital General Zona 2, IMSS, Hermosillo, México), Estrella Araus (Hospital Barros Luco Trudeau, Santiago, Chile), Gonzalo Ardao (Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay), Lilia A. Arellano-Jimenez (Universidad de Guadalajara, Guadalajara, Mexico), Felipe Argandoña (Hospital San Borja Arriaran, Santiago, Chile), Claudia Arias (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Ricardo Armisen (Universidad de Chile, Santiago, Chile), Mauricio Aspee (Hospital Luis Tisne, Santiago, Chile), Rodrigo Assar (Universidad de Chile, Santiago, Chile), Itzel...
### TABLE 8 | Distribution of Latin American women with breast cancer by PAM50 subtypes according to reproductive and hormonal characteristics, previous benign breast diseases, first-degree family history of breast cancer, and tumor clinical stage at diagnosis.

| Reproductive, hormonal and breast cancer history, and characteristics of the tumor and treatment | PAM50 intrinsic subtype | Total | p-value* |
|---|---|---|---|
| | Luminal A | Luminal B | HER2-enriched | Basal-like | Normal | |
| n | % | n | % | n | % | n | % | n | % |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Age range at menarche** | | | | | | | | | |
| Up to 12 years | 174 | 47.0 | 88 | 47.6 | 35 | 31.8 | 65 | 46.4 | 26 | 44.8 | 388 | 45.0 | 0.078 |
| 13 years and over | 193 | 52.2 | 94 | 50.8 | 72 | 65.5 | 72 | 51.4 | 32 | 55.2 | 463 | 53.7 | |
| Unknown | 3 | 0.8 | 3 | 1.6 | 3 | 2.7 | 3 | 2.1 | 0 | 0.0 | 12 | 1.4 | |
| **Oral contraceptive use** | | | | | | | | | |
| Ever use | 227 | 61.4 | 116 | 62.7 | 57 | 51.8 | 89 | 63.6 | 32 | 55.2 | 521 | 60.4 | 0.354 |
| Never use | 141 | 38.6 | 67 | 36.2 | 50 | 45.5 | 51 | 36.4 | 26 | 44.8 | 335 | 38.6 | |
| Unknown | 2 | 0.5 | 2 | 1.1 | 3 | 2.7 | 0 | 0.0 | 0 | 0.0 | 7 | 0.8 | |
| **At least one full pregnancy** | | | | | | | | | |
| Yes | 335 | 90.5 | 160 | 86.5 | 101 | 91.8 | 132 | 94.3 | 53 | 91.4 | 781 | 90.5 | 0.316** |
| No | 31 | 8.4 | 22 | 11.9 | 7 | 6.4 | 8 | 5.7 | 4 | 6.9 | 72 | 8.3 | |
| Unknown | 4 | 1.1 | 3 | 1.6 | 2 | 1.8 | 0 | 0.0 | 1 | 1.7 | 10 | 1.2 | |
| **Breastfeeding** | | | | | | | | | |
| Yes | 301 | 81.4 | 141 | 76.2 | 82 | 74.5 | 117 | 83.6 | 49 | 84.5 | 690 | 80.0 | 0.125 |
| No* | 59 | 15.9 | 40 | 21.6 | 26 | 23.6 | 21 | 15.0 | 7 | 12.1 | 153 | 17.7 | |
| Unknown | 10 | 2.7 | 4 | 2.2 | 2 | 1.8 | 2 | 1.4 | 2 | 3.4 | 23 | 2.9 | |
| **Menopause status and age** | | | | | | | | | |
| Premenopausal | 135 | 36.5 | 57 | 30.8 | 33 | 30.0 | 52 | 37.1 | 24 | 41.4 | 301 | 34.9 | 0.099 |
| Up to 50 years | 147 | 39.7 | 88 | 47.6 | 43 | 39.1 | 51 | 36.4 | 21 | 36.2 | 350 | 40.6 | |
| 51 years and over | 53 | 14.3 | 16 | 8.6 | 20 | 18.2 | 13 | 9.3 | 5 | 8.6 | 107 | 12.4 | |
| Unknown | 35 | 9.5 | 24 | 13.0 | 14 | 12.7 | 24 | 17.1 | 8 | 13.8 | 105 | 12.2 | |
| **Hormone replacement therapy** | | | | | | | | | |
| Yes | 37 | 10.0 | 27 | 14.6 | 14 | 12.7 | 22 | 15.7 | 4 | 6.9 | 104 | 12.1 | |
| No | 330 | 89.2 | 153 | 82.7 | 94 | 85.5 | 117 | 83.6 | 54 | 93.1 | 748 | 86.7 | 0.188** |
| Unknown | 3 | 0.8 | 5 | 2.7 | 2 | 1.8 | 1 | 0.7 | 0 | 0.0 | 11 | 1.3 | |
| **Self-reported previous benign breast diseases** | | | | | | | | | |
| Yes | 223 | 60.3 | 112 | 60.5 | 57 | 51.8 | 73 | 52.1 | 35 | 60.3 | 500 | 57.9 | 0.277 |
| No | 147 | 39.7 | 73 | 39.5 | 53 | 48.2 | 67 | 47.9 | 23 | 39.7 | 363 | 42.1 | |
| **First-degree family history of breast cancer** | | | | | | | | | |
| Yes | 31 | 8.4 | 16 | 8.6 | 6 | 5.5 | 9 | 6.4 | 1 | 1.7 | 63 | 7.3 | 0.352 |
| No | 339 | 91.6 | 169 | 91.4 | 104 | 94.5 | 131 | 93.6 | 57 | 98.3 | 800 | 92.7 | |
| **Tumor clinical stage at diagnosis** | | | | | | | | | |
| IIA | 185 | 50.0 | 66 | 35.7 | 33 | 30.0 | 30 | 21.4 | 17 | 29.3 | 331 | 38.4 | <0.001 |
| IIB | 116 | 31.4 | 58 | 31.4 | 34 | 30.9 | 47 | 33.6 | 19 | 32.8 | 274 | 31.7 | |
| IIIB | 35 | 9.5 | 43 | 23.2 | 31 | 28.2 | 50 | 35.7 | 15 | 25.9 | 174 | 20.2 | |
| IIIC | 34 | 9.2 | 18 | 9.7 | 12 | 10.9 | 13 | 9.3 | 7 | 12.1 | 84 | 9.7 | |

*The p-value of Chi-square test does not include the category unknown. **The p-value of Fisher’s test does not include the category Unknown. *Includes never pregnant women.
Erika Carvallo (Hospital San Borja Arriarán, Santiago, Chile), Julio Carzoglio (Instituto Nacional del Cáncer, Santiago, Chile), Monica Casalnuovo (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Benedicita Caserta (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Alvaro Castillo (Hospital San José, Santiago, Chile), César Castillo (Hospital Barros Luco Trudeau, Santiago, Chile), Juan M. Castro-Cervantes (Hospital de Especialidades, CMNO-IMSS, Guadalajara, México), Yascara Cerda (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Roger Chammas (Instituto de Cáncer de São Paulo, São Paulo, Brasil), Mario Alberto Chavez-Zamudio (Hospital General No 1, IMSS, Obregon, México), Loreto Chia (Hospital San José, Santiago, Chile), Daniela Chirico (Fundación Instituto Leloir, CONICET, Buenos Aires, Argentina), Esther Cisneros-Quirarter (Universidad de Guadalajara, Guadalajara, México), Minor Raúl Cordero-Bautista (Hospital Luis Tisne, Santiago, Chile), Valeria Connejo (Hospital San Borja Arriarán, Santiago, Chile), Baldemar Corral-Villegas (Centro Estatal de Oncología, Hermosillo, México), Andrés Cortés (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), German Salvador Cortez-Zamorano (Universidad de Sonora, Hermosillo, México), Alejandro Corvalán (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Adolfo Cruz (Hospital Barros Luco Trudeau, Santiago, Chile), Alba d’Aurora (Hospital San Borja Arriarán, Santiago, Chile), Sandra De la Fuente (Universidad de Chile, Santiago, Chile), Soledad De la Peña (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Roberto de Leon-Caballero (Hospital General del Estado de Sonora, Hermosillo, México), César Del Castillo (Hospital San Borja Arriarán, Santiago, Chile), Azucena Del-Toro-Valero (Universidad de Guadalajara, Guadalajara, México), Mirtha Di Pretoro (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Andrea Dígonzelli (Hospital Regional de Agudos Eva Perón, Buenos Aires, Argentina), Jose El Ters (Instituto Nacional de Cáncer, Montevideo, Uruguay), Paula Escobar (Hospital Luis Tisne, Santiago, Chile), Marcela Estolaza (Hospital Luis Tisne, Santiago, Chile), Adriane Feijo (Hospital de Cáncer de Barretos, Barretos, Brasil), Marcelo Fanelli (AC Camargo Cancer Center, São Paulo, Brazil), Paulo Farias (Coordination of Prevention and Surveillance, Instituto Nacional de Cáncer, Rio de Janeiro, Brazil), Diego Flaks (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Edgar G. Flores-Ayala (Instituto Jalisienço de Cancerología, Guadalajara, Mexico), Maria R. Flores-Marquez (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), David Franco-Hughes (Universidad de Sonora, Hermosillo, Mexico), Karina Franco-Topete (OPD Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico), Cristobal Fresno (Universidad Católica de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología-CONICET, Córdoba, Argentina), Carolina Gabay (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Mario Gallegos (Hospital San Borja Arriarán, Santiago, Chile), Jorge Gamboa (Hospital San Borja Arriarán, Santiago, Chile), Daiana Ganiewich (Fundación Instituto Leloir, CONICET, Buenos Aires, Argentina), Carlos Garbovsky (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Ricardo García-Gaeta (Universidad de Guadalajara, Guadalajara, México), Alma C. García-Martinez (Universidad de Guadalajara, Guadalajara, México), Rubén Alejandro García-Munguia (Hospital de Ginecopediatría, Hermosillo, México), Adriana Garibay-Escobar (Universidad de Sonora, Hermosillo, México), Liliana Gimenez (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Maríana M. Gomez-Del Toro (Universidad de Guadalajara, Guadalajara, México), Germán González (Universidad Católica de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología-CONICET, Córdoba, Argentina), César Osbaldo González-Mondaca (Hospital General Zona 2, IMSS, Hermosillo, México), Leivy P. Gonzalez-Ramirez (Universidad de Guadalajara, Guadalajara, México), Beatriz Gonzalez-Ulloa (Hospital de Especialidades, CMNO-IMSS, Guadalajara, México), Susana Gorostidy (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Gonzalo Greif (Institut Pasteur de Montevideo, Montevideo, Uruguay), Alfonso G.Guevara-Torres (Centro Estatal de Oncología, Hermosillo, México), Lorena Gutierrez (Hospital San Borja Arriarán, Santiago, Chile), Adrián Hannois (Hospital Regional de Agudos Eva Perón, Buenos Aires, Argentina), Andrew Hart (Universidad de Chile, Santiago, Chile), Steffen Härtel (Universidad de Chile, Santiago, Chile), Marcos Henriquez (Hospital Barros Luco Trudeau, Santiago, Chile), Miriam E Hernandez-Franco (Universidad de Guadalajara, Guadalajara, México), Rafael Hernandez-Guevara (Hospital General No 1, IMSS, Obregon, México), Manuel I Herrera-Miramontes (Universidad de Guadalajara, Guadalajara, México), Graciela Horton (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Gladys Ibáñez (Hospital San José, Santiago, Chile), Martín Ipiña (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Lilian Jara (Universidad de Chile, Santiago, Chile), Raul Jara (Hospital Luis Tisne, Santiago, Chile), Maria Luisa Jaramillo (Hospital San Borja Arriarán, Santiago, Chile), Beatrix Jardim (Coordination of Prevention and Surveillance, Instituto Nacional de Cáncer, Rio de Janeiro, Brazil), Maria Eugenia Jimenez (Hospital Barros Luco Trudeau, Santiago, Chile), Victor M. Jimenez-Moreno (Hospital de Gineco-Obstetricia, CMNO-IMSS, Guadalajara, México), Hugo Ju (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Nazareth Juárez Rusjan (Instituto de Oncología Angel Roffo, Buenos Aires, Argentina), Karen Juneman (Hospital Luis Tisne, Santiago, Chile), Ligia Maria Kerr (Hospital de Cáncer de Barretos, Barretos, Brazil), Alejandro Krupelis (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Guillermo Laviña (Hospital de Clínicas Manuel Quintela, Universidad de la República, Montevideo, Uruguay), Fernando Lavista (Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay), Irma Leticia León-Duarte (Hospital General del Estado de Sonora, Hermosillo, México), Alberto Lescano (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Verónica Lezano (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Rossana
Mendoza Lopez (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Jose Guillermo López-Cervantes (Universidad de Sonora, Hermosillo, Mexico), Miguel Enrique Lopez-Muñoz (Universidad de Sonora, Hermosillo, Mexico), Francisa Lucena (Coordination of Prevention and Surveillance, Instituto Nacional de Cáncer, Río de Janeiro, Brazil), Alejandra Luque (Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay), Alejandro Maass (Universidad de Chile, Santiago, Chile), Maria do Socorro Maciel (AC Camargo Cancer Center, São Paulo, Brazil), Silvina Maldonado (Hospital Regional de Chile), Flavia Rotea Mangone (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Jorge Mansilla (Universidad de Chile, Santiago, Chile), Katherine Marcelain (Universidad de Chile, Santiago, Chile), Carolina Mariani (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Marcia Maria Chiquitelli Marques (Hospital de Cáncer de Barretos, Barretos, Brazil), Reyna J Martinez-Arriaga (Universidad de Guadalajara, Guadalajara, Mexico), Héctor R Martinez-Ramirez (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), Marcela Martins (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Alma G Maya-Gonzalez (Universidad de Guadalajara, Guadalajara, Mexico), Mariana Menini (Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay), Soledad Milans (Hospital de Clínicas Manuel Quintela, Universidad de la República, Montevideo, Uruguay), Soledad Montes (Instituto Nacional del Cáncer, Santiago, Chile), Ana Verónica Morales-Hernández (Universidad de Sonora, Hermosillo, Mexico), Carla Morong (Hospital San Borja Arriarán, Santiago, Chile), Eduardo Mussetti (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Luis J Najar-Acosta (Universidad de Guadalajara, Guadalajara, Mexico), Elisa Napolitano e Ferreira (AC Barretos, Barretos, Brazil), Flavia Rotea (Hospital de Cáncer, Rio de Janeiro, Brazil), Cynthia Aparecida Bueno de Toledo Oso (Universidad de la República, Montevideo, Uruguay), Flavia Rotea (Hospital Luis Tisne, Santiago, Chile), Nilton Onari (Hospital de Cáncer de Barretos, Barretos, Brazil), Emma M Oropeza-De Anda (Universidad de Guadalajara, Guadalajara, Mexico), David Ortega-Tirado (Universidad de Sonora, Hermosillo, Mexico), Miguel Angel Ortiz-Martinez (Hospital General No 1, IMSS, Obregón, México), Cynthia Aparecida Bueno de Toledo Osorio (AC Camargo Cancer Center, São Paulo, Brazil), Carlos Eduardo Paiva (Hospital de Cáncer de Barretos, Barretos, Brazil), Paulina Peñaloza (Hospital Luis Tisne, Santiago, Chile), Miguel Peredo-Navarro (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), David Pereira (Instituto de Oncología Angel Rofo, Buenos Aires, Argentina), Laura Perez-Michel (Hospital General No 1, IMSS, Obregón, México), Francisca Pino (Hospital Barros Luco Trudeau, Santiago, Chile), Elsa Pinto (Hospital Luis Tisne, Santiago, Chile), Natalia Pinto (Hospital Luis Tisne, Santiago, Chile), Jessica Pizarro (Hospital Barros Luco Trudeau, Santiago, Chile), Jael Quintero (Universidad de Sonora, Hermosillo, Mexico), Antonio Quintero-Ramos (Universidad de Guadalajara, Guadalajara, Mexico), Enrique Ramirez (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Gladys E Ramirez-Rosas (Universidad de Guadalajara, Guadalajara, Mexico), Claudia Ramis (Hospital San José, Santiago, Chile), Maritza Ramos-Ramírez (Universidad de Guadalajara, Guadalajara, Mexico), Adela Rascon-Alcántar (Hospital de Ginecología, Hermosillo, México), Francois Richard (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile), Omar Rios-Mendoza (Hospital General del Estado de Sonora, Hermosillo, México), ErnestoRivera-Claisse (Centro Estatal de Oncología, Hermosillo, México), Ramón E.Robles-Zepeda (Universidad de Sonora, Hermosillo, Mexico), Iara Santana Rocha (Hospital de Cáncer de Barretos, Barretos, Brazil), Natalia Rodriguez (Hospital Barros Luco Trudeau, Santiago, Chile), Vilma Rodriguez (Hospital Barros Luco Trudeau, Santiago, Chile), Maria Teresa Rodriguez (Hospital San José, Santiago, Chile), Diego Rodríguez-Gonzalez (Universidad de Guadalajara, Guadalajara, Mexico), Rosemire A Roela (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Ana M. Romero-Gomez (Universidad de Guadalajara, Guadalajara, Mexico), Ana M. Rosales-Sandoval (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), Lidia A. Rubio-Chavez (Universidad de Guadalajara, Guadalajara, Mexico), Omar V. Rubio-Plascencia (Universidad de Guadalajara, Guadalajara, Mexico), Florencia Russo (Hospital Regional de Agudos Eva Perón, Buenos Aires, Argentina), Gaciela Sabini (Programa Nacional para el Control del Cancer, Montevideo, Uruguay), Isabel Saffie (Hospital Luis Tisne, Santiago, Chile), Brenda Samaniego (Universidad de Sonora, Hermosillo, Mexico), Benito Sanchez-Llamas (Hospital de Gineco-Obstetricia, CMNO-IMSS, Guadalajara, Mexico), Verónica Sanchotena (Hospital Municipal de Oncología Maria Curie, Buenos Aires, Argentina), Daniel Sat-Muñoz (Hospital de Gineco-Obstetricia, CMNO-IMSS, Guadalajara, Mexico), Mariana Savignano (Instituto de Oncología Angel Rofo, Buenos Aires, Argentina), Cristovam Scapulatempo Neto (Hospital de Cáncer de Barretos, Barretos, Brazil), Max Mano Senna (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Carolina Silva (Hospital San Borja Arriarán, Santiago, Chile), Jaime Silvera (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Isabele Small (Coordination of Prevention and Surveillance, Instituto Nacional de Cáncer, Río de Janeiro, Brazil), Fernando Soares (Coordination of Prevention and Surveillance, Instituto Nacional de Cáncer, Río de Janeiro, Brazil), Iberê Soares (Instituto de Cáncer de São Paulo, São Paulo, Brazil), Silvana Soares dos Santos (AC Camargo Cancer Center, São Paulo, Brazil), Evandro Sobrosa de Mello (Instituto de Cáncer de São Paulo, São Paulo, Brazil), José Antonio Sola (Instituto Nacional del Cáncer, Santiago, Chile), Irene Sorín (Hospital Regional de Agudos Eva Perón, Buenos Aires, Argentina), Alejandra Sosa (Programa Nacional para el Control del Cancer, Montevideo, Uruguay), Claudio Sosa (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Cristianó de Pádua Souza (Hospital de Cáncer de Barretos, Barretos, Brazil), Lucía Spangenberg (Institut Pasteur de Montevideo, Montevideo, Uruguay), Gustavo Steffanof (Coordination of Prevention and Surveillance, Instituto
Nacional de Cáncer, Río de Janeiro, Brazil), Florencia Strominsky (Fundación Instituto Leloir, CONICET, Buenos Aires, Argentina), Mónica Tapia (Hospital Luis Tisne, Santiago, Chile), Raziel O. Tapia-Llanos (Universidad de Guadalajara, Guadalajara, Mexico), Gerónimo M. Tavares-Macias (Hospital de Especialidades, CMNO-IMSS, Guadalajara, Mexico), Verónica Terziff (Centro Hospitalario Pereira Rossell, Montevideo, Uruguay), Vicente Teti (Hospital Municipal de Oncología Maria Curie, Buenos Aires, Argentina), Javier Tognarelli (Instituto de Salud Pública, Santiago, Chile), Verónica Toledo (Hospital Luis Tisne, Santiago, Chile), Paulina Toro (Hospital Luis Tisne, Santiago, Chile), Roberto Torres (Instituto Nacional del Cáncer, Santiago, Chile), Mariana Torres-Palomares (Universidad de Guadalajara, Guadalajara, Mexico), Alejandra Trinchero (Hospital Regional de Agudos Eva Perón, Buenos Aires, Argentina), Rogelio Troyo-San Roman (Universidad de Guadalajara, Guadalajara, Mexico), Hernan Urbano (Hospital Barros Luco Trudeau, Santiago, Chile), Nicolas Vacca (Programa Nacional para el Control del Cáncer, Montevideo, Uruguay), Maria Lourdes Valencia-Peña (Universidad de Sonora, Hermosillo, Mexico), Jaime Vazquez-Nares (Instituto Jalisciense de Cancerología, Guadalajara, Mexico), Ezequiel Velez-Gomez (OPD Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico), Laura N. Venegas-Godinez (Universidad de Guadalajara, Guadalajara, Mexico), Ricardo Verdugo (Universidad de Chile, Santiago, Chile), René Aloisio da Costa Vieira (Hospital de Cáncer de Barretos, Barretos, Brazil), Manuel Isaac Villegas-Gómez (Universidad de Guadalajara, Guadalajara, Mexico), Silvia Vornetti (Hospital Municipal de Oncología María Curie, Buenos Aires, Argentina), Anapaula H. U. Watanabe (Hospital de Cáncer de Barretos, Barretos, Brazil), Carlos Zamorano (Hospital Barros Luco Trudeau, Santiago, Chile), Luis Zapata (Hospital Barros Luco Trudeau, Santiago, Chile), Zdenka Zlatar (Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile).

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the National Cancer Institute ethics committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
Conceptualization, design, investigation, supervision, data collection, data curation, statistical analysis, writing, reviewing, and editing: LA, SCo, MV, OV, LC-S, MSo, and RB. Conceptualization, supervision, investigation and data collection, funding acquisition, reviewing, and editing: EAb, NA, AD-N, AL, BM, OP, CV, MB, and JF. Conceptualization, interpretation, writing, reviewing, and editing: BJo and MSz. Investigation and data collection: EAI, IA, AB, NC, DC, MCa, SCA, ACa, MCE, ACS, SCR, AT-A, RD-C, LD, EF, JF, WF, RF-T, FG, JG, LG-R, MG, SG-R, BJ, AL-V, DL, SM, AM-M, GM-V, CM, MN, AO-V, RR, JR, RR, CR, ES-G, LS, JS, AS-G, SV, LZ, and United States-Latin American Cancer Research Network (US-LACRN). All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING
This study was partially supported by the Center for Global Health at the United States - National Cancer Institute at the National Institutes of Health (contract award # HHSN2612010000871/NO2-PC-2010-00087) and by the official agencies of each country.

ACKNOWLEDGMENTS
We thank all personnel from Westat, in particular Vanessa Olivo, Kerry Grace Morrissey, and Kathy Clingan, for their hard work coordinating data curation. We also acknowledge the personnel from Leidos, in particular Mariana González del Riego and Silvina Frech during the step of US-LACRN capacity building. We thank the enormous valuable help of Dr. Mark Cosentino in biobank setup, Dr. James Robb in pathology good practices, and Dr. Katherine Hoadley in microarray analysis and PAM50 classification. We thank all personnel committed with epidemiological interviews in all places. We finally want to thank all the patients that took part in this study for their generous collaboration with data and biospecimens and their commitment to the advancement of breast cancer knowledge in Latin America.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.845527/full#supplementary-material

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660
2. Bertos NR, Park M. Breast Cancer — One Term, Many Entities? J Clin Invest (2011) 121(10):3789–96. doi: 10.1172/JCI57100
3. Bradley CJ, Given CW, Race RC. Socioeconomic Status, and Breast Cancer Treatment and Survival. J Natl Cancer Inst (2002) 94(7):490–6. doi: 10.1093/jnci/94.7.490
4. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. Cancer Epidemiol Biomarkers Prev (2007) 16 (3):439–43. doi: 10.1158/1055-9965.EPI-06-0806
5. Kwan ML, Kushn LH, Wetzstein E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of Breast Cancer Subtypes in Two Prospective Cohort Studies
